One analogy for investors' view on the drugmaker is football, according to Cramer.
"I like run, I like pass, but Wall Street wants passing, and Gilead is sitting on the ball," Cramer said. "Gilead is just doing two yards, two yards, and then they've gained six yards and they have to punt. And that's why people don't like Gilead."
While the company has ample financial capacity to step up its M&A game given its available cash on hand -- $6.3 billion as of March 31 -- whether it plans to execute on a more transformative deal in the near term remains uncertain.
Potential targets for the Foster City, Calif., pharmaceutical company include liver drugmaker Intercept (ICPT) - Get Report and oncology pharmaceutical company Incyte (INCY) - Get Report , TheStreet previously reported.
Gilead in April agreed to shell out $400 million for biotech company Nimbus Apollo. In December, the company spent $725 million to inherit a minority stake in Belgian biotech firm Galapagos, gaining access to license an experimental rheumatoid arthritis treatment that ended with AbbVie (ABBV) - Get Report in September.
The drugmaker earlier this week appointed two new members to its executive board -- Executive Vice President of Commercial Operations Kevin Young was named COO while Martin Silverstein was named executive vice president of strategy.
With a market capitalization of nearly $114 billion, shares of Gilead slid about 1.3% to $85.36 on Thursday afternoon.